<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="16123">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02896985</url>
  </required_header>
  <id_info>
    <org_study_id>P15-770</org_study_id>
    <nct_id>NCT02896985</nct_id>
  </id_info>
  <brief_title>Observational Study Evaluating the Effectiveness of Drug Concentration to Predict the Recapture of Response in Crohn's Disease Patients With Loss of Response</brief_title>
  <acronym>PRADA</acronym>
  <official_title>A Cohort Study to Evaluate the Effectiveness of Drug Concentrations in Predicting Recapture of Response With Weekly ADAlimumab in Crohn's Disease Subjects With Secondary Loss of Response (PRADA)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AbbVie</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AbbVie</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multi-center study that explores the relationship between recapture of response
      with escalation to weekly adalimumab and trough adalimumab concentration before escalation
      in patients experiencing lack of response (LOR).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2016</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Explore the relationship between drug concentration at baseline and recapture of response</measure>
    <time_frame>At Week 12</time_frame>
    <description>Logistic regression analysis will be used to model the relationship between drug concentration at baseline and recapture of response.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Explore the relationship between trough adalimumab concentrations at baseline and change in patient reported outcome 2 (PRO2)</measure>
    <time_frame>From Week 0 to Week 12</time_frame>
    <description>Linear regression analysis is used.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Explore the relationship between trough adalimumab concentrations at baseline and change in C-reactive protein (CRP)</measure>
    <time_frame>From Week 0 to Week 12</time_frame>
    <description>Linear regression analysis is used.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Explore the relationship between trough adalimumab concentrations at baseline and change in fecal calprotectin</measure>
    <time_frame>From Week 0 to Week 12</time_frame>
    <description>Linear regression analysis is used.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants with clinical response</measure>
    <time_frame>At Week 12</time_frame>
    <description>It is defined as an 8 point drop in Patient Reported Outcome 2 (PRO2) with a 50% decrease in either C-Reactive Protein (CRP) or fecal calprotectin from screening and/or normalization of CRP (&lt;5) or calprotectin (&lt;100)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants with clinical remission PRO2 &lt; 8</measure>
    <time_frame>At Week 12</time_frame>
    <description>PRO2 was developed based on FDA guidance for use of patient reported outcomes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants with 50% drop from screening in CRP or calprotectin</measure>
    <time_frame>At Week 12</time_frame>
    <description>Assessing participants with 50% drop in CRP or calprotectin.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants with normalization of CRP or fecal calprotectin</measure>
    <time_frame>At Week 12</time_frame>
    <description>Assessing participants with normalization of CRP (&lt;5mg/dl) or fecal calprotectin (&lt;150ug/ml)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants requiring steroids or additional therapy</measure>
    <time_frame>Up to Week 12</time_frame>
    <description>Assessing participants that require steroids or additional therapy</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Crohn's Disease</condition>
  <arm_group>
    <arm_group_label>Participants with Crohn's disease</arm_group_label>
    <description>Participants who have developed LOR to adalimumab after a minimum of 16 weeks of treatment.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Participants will be enrolled from approximately 15 to 20 investigative sites in Canada
        where such Therapeutic Drug Monitoring/Anti-Adalimumab Antibody (TDM/AAA) testing at the
        point of patient LOR and pre-dose escalation to Every Week (EW) occurs.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Documented diagnosis of Crohn's Disease.

          -  Treatment with adalimumab, for a minimum of 16 weeks, as per clinical practice, at a
             dose of 160 mg at week 0, 80 mg at week 2, and then 40 mg q2w with a documented
             response as defined by the investigator.

          -  Current evidence of active disease/LOR defined as a PRO2 score &gt; 14 and the presence
             of active inflammation (confirmed with a CRP &gt; 5 and/or a fecal calprotectin of
             greater than 250Âµg/g.

          -  Ability of subject to participate fully in all aspects of this clinical trial.

          -  Written informed consent must be obtained and documented.

        Exclusion Criteria:

          -  Primary non-responders to 16 weeks of adalimumab therapy.

          -  Received any investigational drug within the 16 weeks of adalimumab therapy.

          -  Serious underlying disease other than CD that, in the opinion of the investigator,
             may interfere with the subject's ability to participate fully in the study.

          -  History of alcohol or drug abuse that, in the opinion of the investigator, may
             interfere with the subject's ability to comply with the study procedures.

          -  Stools positive for Clostridium difficile.

          -  Pregnant or lactating women.

          -  Current enrolment in any other interventional research study.

          -  Presence of perianal or abdominal abscess.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christina Pelizon, MD</last_name>
    <role>Study Director</role>
    <affiliation>AbbVie</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nathalie Foucault</last_name>
    <phone>514 832-7702</phone>
    <email>nathalie.foucault@abbvie.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Julie Charbonneau</last_name>
    <phone>514 832-7197</phone>
    <email>julie.charbonneau@abbvie.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 157893</name>
      <address>
        <city>Calgary</city>
        <zip>T2P 1H9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 157893, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 153127</name>
      <address>
        <city>Cambridge</city>
        <zip>N1S 2M6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 153127, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 155224</name>
      <address>
        <city>Edmonton</city>
        <zip>T6G 2B7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 155224, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 152454</name>
      <address>
        <city>Halifax</city>
        <zip>B3H 2Y9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 152454, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 151996</name>
      <address>
        <city>Hamilton</city>
        <zip>L8S 4K1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 151996, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 155493</name>
      <address>
        <city>Levis</city>
        <zip>G6V 3Z1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 155493, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 152508</name>
      <address>
        <city>London</city>
        <zip>N6A 5A5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 152508, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 155184</name>
      <address>
        <city>Montreal</city>
        <zip>H1T 2M4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 155184, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 151997</name>
      <address>
        <city>Montreal</city>
        <zip>H3G 1A4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 151997, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 153772</name>
      <address>
        <city>Montreal</city>
        <zip>H3P 3E5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 153772, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 152507</name>
      <address>
        <city>New Westminster</city>
        <zip>V3L 3W5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 152507, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 151998</name>
      <address>
        <city>Oshawa</city>
        <zip>L1H 7K4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 151998, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 153771</name>
      <address>
        <city>Ottawa</city>
        <zip>K1H 8L6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 153771, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 157976</name>
      <address>
        <city>Sherbrooke</city>
        <zip>J1G 2E8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 157976, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 155262</name>
      <address>
        <city>Toronto</city>
        <zip>M5G 1X5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 155262, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 152509</name>
      <address>
        <city>Vaughan</city>
        <zip>L4L 4Y7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 152509, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 154682</name>
      <address>
        <city>Victoria</city>
        <zip>V8T 5G4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 154682, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <link>
    <url>http://www.rxabbvie.com/</url>
  </link>
  <verification_date>February 2017</verification_date>
  <lastchanged_date>February 3, 2017</lastchanged_date>
  <firstreceived_date>September 7, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>C-Reactive Protein (CRP)</keyword>
  <keyword>Anti-Adalimumab Antibody (AAA)</keyword>
  <keyword>Therapeutic Drug Monitoring (TDM)</keyword>
  <keyword>Patient Reported Outcome 2 (PRO 2)</keyword>
  <keyword>Adalimumab</keyword>
  <keyword>Harvey Bradshaw Index (HBI)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Crohn Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Adalimumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
